![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEieddFqhhuCMNmaxPoO2V8GbCO0remMr0gAPZHcLS0DXvTPBavJkFNjgQCf8hxFyjuCq6srX8ZwBd3IwStGvFQZkdDWxk_v0t3Oy43ZhV2JBGDuLuFlcAl4HbZAy94XAjdkOoDdOAPvUEo/s1600/EVOK+2013-01+daily.png)
Jan 2014 update
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhG5GVu62ZTxky0W3L17ebf8wY9rmqn1P2hVFneFw-HChVqv7oapIqSYbvxwLc4gMO8LhaguvLP5YYkOkOIHsn6z2485V3vNyBnDRMsN2TX6KFZC3xLLTRYDeh4Q6G_hI0f6CjMRgB6SUY/s1600/EVOK+2013-12+daily.png)
Description
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.
Address
Suite 385, 12555 High Bluff Drive
SAN DIEGO, CA 92130
United States
SAN DIEGO, CA 92130
United States
Website
http://www.evokepharma.comKey stats and ratios
Q2 (Jun '13) | 2012 | |
Net profit margin | - | - |
Operating margin | - | - |
EBITD margin | - | - |
Return on average assets | -55.40% | -395.07% |
Return on average equity | - | - |
Employees | 2 |
No comments:
Post a Comment